media thickness (cIMT), electrocardiography (ECG) and echocardiography with assessment of ejection fraction (EF) and diastolic dysfunction (E/A ratio).

**Results:** The significant differences between male vs female RA patients included: higher mean values of cIMT [0.93 (0.19) vs 0.80 (0.22) mm, p=0.04], atherogenic index [4.2 (1.4) vs 3.5 (1.0), p=0.03] and SCORE [5.7 (3.7) vs 2.8 (2.7), p<0.001]; as well as lower concentration of HDL-cholesterol [50.2 (12) vs 59.1±9 mg/dl, p=0.04] and NT-proBNP [66.6 (61.2) vs 106.8 (61.5) pmol/l, p=0.0006]. The mean values of age, disease duration, DAS28, C-reactive protein, body mass index, BP, QTC, E/A and EF were not significantly different in male and female patients with RA of low activity.

In the control group no significant differences were observed between male and female subjects, when considering: age, cIMT, BP, QTC, EF, E/A.

All the male RA patients had features of subclinical or advanced atherosclerosis (cIMT ≥0.6 mm), there were no male patients with normal cIMT (<0.6 mm). In controls no cIMT was found in 5 (33.3%) and subclinical atherosclerosis in 10 (66.7%), there was no control subject with advanced atherosclerosis (c>0.1).

The mean age of patients and controls did not differ significantly.

**Conclusions:** The results of the study suggest an unfavourable CV risk profile in male RA patients with low disease activity. The higher CV risk was observed in male RA patients in comparison with both controls of comparable age, as well as with female RA patients of comparable age, disease duration and activity. It seems that the male gender contributes considerably to CV risk in the period of low RA activity.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.3142

---

**AB0209**

**OPTIMISATION OF ULTRASONOGRAPHIC EXAMINATION FOR THE DIAGNOSIS OF EROSIve RHEUMATOID ARTHRITIS VERSUS EROSIve OSTEOARTHRITIS WITH RADIOGRAPHY CONSIDERED AS GOLD STANDARD**

C. Roux, F. Gandjbakhch, A. Pierreinsnard, C. Luksas, R. Masri, J.-P. Sommier, I. Clerc-Urmes, C. Baumann, I. Chary-Valckenaere, D. Leouelle, 

**Rheumatology, University Hospital of Nancy, Vandoeuvre-lès-Nancy; 
Rheumatology, Academic Hospital Pitié Salpêtrière, Paris; 
Rheumatology, University Hospital Clermont-Ferrand; 
Rheumatology, University Hospital of Lapeyronie, Montpellier; 
Rheumatology, University Hospital of Nancy, Vandoeuvre-lès-Nancy; 
Platform of Clinical Research Support PARC, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France**

**Background:** Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease responsible for structural damage. Radiography (RX) is considered as the gold standard for visualising and quantifying bone lesions in RA.

**Musculoskeletal ultrasound (US) is booming in clinical practice for the diagnosis of erosive RA.**

**Objectives:** To determine thresholds and better scenarios for the diagnosis of erosive RA by US in RA and osteoarthritic (OA) patients.

**Methods:** Patients fulfilling ACR 1987 and/or ACR/EULAR 2010 criteria for RA or hand OA criteria were prospectively included. A modified Sharp erosion score was considered as the gold standard for visualising and quantifying bone lesions in RA.

**Results:** Of the 18 patients included in the study, all 18 were examined at T0, T1 and T2, and 17 patients were evaluated at T3. All clinical and laboratory measures, as well as MSUS scores, were significantly reduced during follow-up. There was a significant correlation between MSUS scores and conventional (clinical and laboratory) measures of disease activity. Correlation coefficients between the different parameters and factors potentially predicting response to tofacitinib will be reported.

**Conclusions:** A positive response to tofacitinib treatment was shown both in RA and OA patients, with good correlation between the methods. In a busy, everyday-clinical practice setting in Hong Kong, MSUS was found to be a useful tool for monitoring disease activity and joint damage in RA patients. The study sought to determine whether US was comparable to conventional techniques for monitoring disease activity and joint damage in RA.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.5054

---

**AB0211**

**THE RELATIONSHIP BETWEEN THE ELEVATED SERUM IMMUNOGLOBULIN G4 LEVEL AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS**


**Keimyung University, Daegu, Korea, Republic of Ireland**

**Background:** High levels of serum immunoglobulin G4 (IgG4) would comprise a useful diagnostic tool in IgG4-related disease, but little information is available about IgG4 in conditions other than IgG4-related disease, including rheumatic diseases. Previous studies indicate that the elevated serum IgG4 in rheumatoid arthritis (RA) is common and disproportional to total IgG.

**Objectives:** The aim of this study is to evaluate the level of serum IgG4 and IgG4/total IgG ratio in patients with RA.

**Methods:** Ninety-six patients with RA and one hundred and thirty-five non-RA controls were enrolled between March 2014 and July 2017. All samples were collected before the treatments. The levels of Serum total IgG and IgG4 were determined by nephelometric assay. The cut-off value of serum IgG4 was 135 mg/dL. Data on clinical variables and disease activity markers, such as numbers of tender and swollen joints, levels of acute phase reactants and disease activity score 28 (DAS28) were recorded in RA patients. We compared the levels of serum IgG4 and the ratio of IgG4/total IgG in rheumatoid arthritis with healthy controls and other rheumatic diseases. This study also investigated the difference the relationship between levels of serum IgG4 and disease activity in RA.